A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice
Dorottya Laczkó,Michael J Hogan,Sushila A Toulmin,Philip Hicks,Katlyn Lederer,Brian T Gaudette,Diana Castaño,Fatima Amanat,Hiromi Muramatsu,Thomas H Oguin,Amrita Ojha,Lizhou Zhang,Zekun Mu,Robert Parks,Tomaz B Manzoni,Brianne Roper,Shirin Strohmeier,István Tombácz,Leslee Arwood,Raffael Nachbagauer,Katalin Karikó,Jack Greenhouse,Laurent Pessaint,Maciel Porto,Tammy Putman-Taylor,Amanda Strasbaugh,Tracey-Ann Campbell,Paulo J C Lin,Ying K Tam,Gregory D Sempowski,Michael Farzan,Hyeryun Choe,Kevin O Saunders,Barton F Haynes,Hanne Andersen,Laurence C Eisenlohr,Drew Weissman,Florian Krammer,Paul Bates,David Allman,Michela Locci,Norbert Pardi,Michael J. Hogan,Sushila A. Toulmin,Brian T. Gaudette,Thomas H. Oguin,Tomaz B. Manzoni,Paulo J.C. Lin,Ying K. Tam,Gregory D. Sempowski,Kevin O. Saunders,Barton F. Haynes,Laurence C. Eisenlohr
DOI: https://doi.org/10.1016/j.immuni.2020.07.019
IF: 32.4
2020-10-01
Immunity
Abstract:SARS-CoV-2 infection has emerged as a serious global pandemic. Because of the high transmissibility of the virus and the high rate of morbidity and mortality associated with COVID-19, developing effective and safe vaccines is a top research priority. Here, we provide a detailed evaluation of the immunogenicity of lipid nanoparticle-encapsulated, nucleoside-modified mRNA (mRNA-LNP) vaccines encoding the full-length SARS-CoV-2 spike protein or the spike receptor binding domain in mice. We demonstrate that a single dose of these vaccines induces strong type 1 CD4+ and CD8+ T cell responses, as well as long-lived plasma and memory B cell responses. Additionally, we detect robust and sustained neutralizing antibody responses and the antibodies elicited by nucleoside-modified mRNA vaccines do not show antibody-dependent enhancement of infection in vitro. Our findings suggest that the nucleoside-modified mRNA-LNP vaccine platform can induce robust immune responses and is a promising candidate to combat COVID-19.
immunology